Introduction
Increasing resistance of Streptococcus pneumoniae to penicillins, cephalosporins, quinolones and macrolides constitutes a growing challenge. Bacteraemia caused by S. pneumoniae remain a major cause of morbidity and mortality, particularly in the elderly. The worldwide prevalence of macrolide resistance varies considerably, being high in Japan, Italy (42%) and France (47.3%), intermediate in the USA (23.3%) and UK (18.4%), and lower in Canada (12%). 1, 2 New ketolides are a promising group of antibiotics against penicillin-and macrolide-resistant strains of S. pneumoniae. Macrolide resistance in S. pneumoniae occurs either by target modification through erm genes, which encode 23S rRNA methylases, and which is associated with a high-level resistance, or through an efflux pump encoded by the mef(E) gene. Recently, insertions in the L4 ribosomal protein of a Canadian S. pneumoniae isolate were found to be associated with reduced susceptibility to the ketolide telithromycin. 3 The objective of this study was to evaluate the in vitro activity of the new ketolide ABT-773 against invasive strains of S. pneumoniae.
Materials and methods

Strains
From 1990 to 1998, all strains of S. pneumoniae isolated from sterile sites (blood, CSF, pleural or articular fluids) were stored and frozen at Ϫ70ЊC. For ABT-773, a recommended breakpoint for susceptibility of р0.5 mg/L was used. 5 
Determination of macrolide-resistance mechanisms
The macrolide-resistance mechanism was determined for 28 erythromycin-resistant S. pneumonia strains by PCR using specific primers as described previously. 
Results and discussion
High levels of in vitro resistance to -lactams and macrolides in S. pneumoniae have been reported throughout the world. However, in many instances the differences in resistance patterns between invasive strains, considered to be always clinically significant, and non-invasive strains have not been clearly established. Some published data indicate that resistance is higher among non-invasive strains, notably those isolated from the respiratory tract or eye specimens. 2 In our study, 8.3% of the strains were resistant to penicillin, 4.7% to cefuroxime, 4.5% to erythromycin, 3.6% to clarithromycin and none to ABT-773 (Table 1) . There were no significant differences between paediatric and adult isolates. Although still low, there was an important increase in the level of resistance to all antibiotics except ABT-773 when comparing the 1990-1994 and 1995-1998 periods. ABT-773 was found to be highly active against all macrolide-resistant strains irrespective of the mode of resistance [erm(B) or mef] . Among the erythromycin-resistant stains, 18 were characterized as erm(B) positive and 10 as mef positive. ABT-773 was also very active against all penicillin non-susceptible (PNSP) strains, with a geometric mean MIC Ͻ 0.06 mg/L ( Table 2 ). For ABT-773, the highest recorded MIC was 0.125 mg/L ( Table  2 ). The two strains with an MIC of 0.125 mg/L were both harbouring the mef determinant. Only 22% (13/59) of PNSP were also resistant to erythromycin. All the penicillinresistant strains were also resistant to cefuroxime; however, none showed reduced susceptibility to ABT-773 using a tentative breakpoint of 0.5 mg/L.
ABT-773 has been shown to be very active against other respiratory pathogens such as Haemophilus influenzae and Moraxella catarrhalis. 7 It also has excellent activity against intracellular Legionella spp., and against Chlamydia pneumoniae. 8 Experimental data have demonstrated that it binds to ribosomes isolated from either susceptible or resistant S. pneumoniae 10-to 100-fold more strongly than erythromycin. 9 In this study, ABT-773 showed excellent in vitro activity against a large number of clinically significant S. pneumoniae strains, irrespective of their resistance patterns. Preliminary data have shown ABT-773 to be bactericidal for S. pneumoniae in vitro, making it a promising new agent against S. pneumoniae infections. 10 In addition, a plasma C max of 0.6 mg/L has been reported after a single 400 mg oral dose, which is four times the highest MIC recorded in this study. This compound may become an option for invasive S. pneumoniae infections in adults and children, and may represent an interesting alternative to the newer quinolones which are targeted towards treatment of Gram-positive infections. 
